Company intelligence / Profile preview

IV BioHoldings

Southport, Connecticut, United Statesivbh.studio ↗

Ownership: Private
Development stage: Preclinical

Overview

IV BioHoldings has developed a portfolio of liquid biopsy-based diagnostic tests targeting early detection of lung cancer, NAFLD, and breast cancer. As of mid/late 2022, the first clinical data readout was expected for their genTRU-breast program with additional readouts and commercial launches planned soon after. The company leverages AI-driven biomarker discovery through partnerships to accelerate development and validation.

Therapeutic areas: OncologyGastroenterology
Modalities: Diagnostic testLiquid biopsy
Industry: Molecular Diagnostics

Partnerships

P4 Diagnostix® – exclusive laboratory partner for assay development & commercializationSonrai Analytics – AI-powered biomarker discovery & algorithm development partner

Beyond the preview

Go deeper on IV BioHoldings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IV BioHoldings.

Explore the full profile